Dacarbazine (DTIC)

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

General information

Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.[1][2]
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 5/27/1975: Initial FDA approval

Also known as

  • Generic names: dacarbazin, imidazole carboxamide
  • Brand names: Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac

References

  1. 1.0 1.1 Dacarbazine (DTIC) package insert
  2. Dacarbazine (DTIC) package insert (locally hosted backup)
  3. Dacarbazine (DTIC) patient drug information (Chemocare)
  4. Dacarbazine (DTIC) patient drug information (UpToDate)